BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Income from sale of Products	1.08B	1.15B	1.02B	877.52M	927.80M
Income from Technology	44.46M	39.22M	75.80M	84.39M	67.78M
Equity Share Income	66.07M	60.04M	61.90M	51.39M	54.58M
Total	1.19B	1.25B	1.16B	1.01B	1.05B

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Overseas	519.71M	575.46M	396.70M	441.36M	488.72M
China	669.79M	672.82M	764.48M	571.93M	561.43M
Total	1.19B	1.25B	1.16B	1.01B	1.05B

Data Source: S&P Global Market Intelligence Last updated: Aug 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error